We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

New Device Detects Brain Tumors Using Urine

By LabMedica International staff writers
Posted on 06 Feb 2023
Print article
Image: Microscopic image of the nanowires (Photo courtesy of Nagoya University)
Image: Microscopic image of the nanowires (Photo courtesy of Nagoya University)

There has recently been an improvement in cancer survival rates due to early detection of the disease, although the survival rate for brain tumors has remained almost the same for the last 20 years, partly due to their late detection. Brain tumors are often discovered only after the onset of neurological symptoms, such as loss of movement or speech, by when the tumor achieves a considerable size. Detecting the tumor when it is still small and commencing treatment as soon as possible can help save lives. Now, researchers have used a new device to identify a key membrane protein in urine that indicates whether a person has a brain tumor. By using the protein to detect brain cancer, it will be possible to avoid invasive tests and increase the chances of the tumor being detected at an early enough stage for surgery. The finding could also have potential implications for detecting other types of cancer.

The presence of tumor-related extracellular vesicles (EVs) in urine can indicate that a person has a brain tumor. EVs are nano-sized vesicles that perform various functions, including cell-to-cell communication. The EVs found in brain cancer patients have specific types of RNA and membrane proteins, allowing them to be used for detecting the presence of cancer and its progression. EVs are excreted far from the brain, but many EVs from cancer cells still exist stably and are excreted in the urine without breaking down.

Researchers at Nagoya University (Nagoya, Japan) have developed a new analysis platform for brain tumor EVs using nanowires at the bottom of a well plate. They used the device to identify two specific types of EV membrane proteins, known as CD31/CD63, from the urine samples of brain tumor patients. By looking for these tell-tale proteins, doctors can identify tumor patients before they develop symptoms. Additionally, urine testing offers several advantages and is an effective, simple, and non-invasive method because urine contains many informative biomolecules that can be traced back to identify the disease.

“Currently, EV isolation and detection methods require more than two instruments and an assay to isolate and then detect EVs,” said Associate Professor Takao Yasui of Nagoya University Graduate School of Engineering. “The all-in-one nanowire assay can isolate and detect EVs using one simple procedure. In the future, users can run samples through our assay and change the detection part, by selectively modifying it to detect specific membrane proteins or miRNAs inside EVs to detect other types of cancer. Using this platform, we expect to advance the analysis of the expression levels of specific membrane proteins in patients’ urinary EVs, which will enable the early detection of different types of cancer.”

Related Links:
Nagoya University 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more


view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.